Sandoz Lawsuit Vs. European Commission Highlights Uncertainties Over Biogenerics
In a decision that took the market by surprise, the European Union’s executive body rejected Sandoz’ application of its Omnitrop generic human growth hormone, citing filing irregularities.
However, Sandoz says it believes it used an appropriate pathway to file the drug, and officials told the media they were engaged in an ongoing dialogue with the...
Already a subscriber? Click here to login